David Simpson

Dave co-founded Iksuda Therapeutics (formerly Glythera) in 2012, refocussing it into an Antibody Drug Conjugate development company underpinned by its proprietary technology platforms. Prior to Iksuda, Dave led Actavis’s biosimilar programmes (now Allergan) and started his industrial career by joining Cobra Biologics (now Cobra Biomanufacturing) before moving to Eden Biodesign Ltd where he led its Process Development capabilities.